Forbes July 23, 2024
Emerging research suggests that cancer therapies such as checkpoint inhibitors could be advanced by targeting a new protein. The protein, known as lymphocyte activation gene-3 or LAG-3, may prove particularly useful in improving patient responses to existing cancer treatments.
Killing Cancer with Checkpoint Inhibitors
Checkpoint inhibitors are an anticancer drug that indirectly attacks tumors. They depend on infusions of antibodies to block proteins called immune checkpoints. Specifically, they target one of three checkpoints: CTLA-4, PD-1 or PD-L1. The antibody barrier formed prevents checkpoint proteins from shutting down immune cells and allows the immune cell to do what it normally does: recognize and attack threats, including tumors.
These inhibitors can treat a wide range of advanced cancers—from lymphomas, lung cancers, skin...
Today's Sponsors
Today's Sponsor